Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.56 |
| ▸ | HMGCR | P04035 | 3/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | PPARD | Q03181 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701316 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL970516 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL7382880 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL6539108 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL3972155 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL3980051 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1702085 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1654498 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1401237 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL7292218 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149820-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-07-18 | — | — | WO | claimed |
| WO-2024133382-A1 | GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| CN-118079021-A | Treatment or amelioration of metabolic disorders using GLP-1 receptor agonists coupled to Gastric Inhibitory Peptide Receptor (GIPR) antagonists | 美国安进公司 | 2024-05-28 | — | — | CN | claimed |
| US-11965039-B2 | Compstatin analogues and their medical uses | ZP SPV 3 K/S (DK) | 2024-04-23 | — | — | US | claimed |
| EP-4351630-A1 | TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS | Antag Therapeutics ApS (DK) | 2024-04-17 | — | — | EP | claimed |
| EP-3551651-B1 | ACYLATED GLP-1/GLP-2 DUAL AGONISTS | ZEALAND PHARMA AS (DK) | 2024-03-06 | — | — | EP | claimed |
| CN-117384274-A | Acylated GLP-1/GLP-2 dual agonists | 西兰制药公司 | 2024-01-12 | — | — | CN | claimed |
| US-20230405087-A9 | ACYLATED GLP-1/GLP-2 DUAL AGONISTS | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | claimed |
| EP-4272751-A2 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | ZP SPV 3 K/S (DK) | 2023-11-08 | — | — | EP | claimed |
| US-20230340039-A1 | NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2023-10-26 | — | — | US | claimed |
| WO-2002076495-A1 | INSULIN PREPARATIONS, WHICH DO NOT CONTAIN ANY ZINC OR ONLY A SMALL QUANTITY OF ZINC AND WHICH HAVE AN IMPROVED STABILITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | WO | claimed |
| EP-1121145-A1 | INSULIN PREPARATIONS FOR PULMONARY DELIVERY CONTAINING MENTHOL | Novo Nordisk A/S (DK) | 2001-08-08 | — | — | EP | claimed |
| EP-1121144-A1 | STABLE CONCENTRATED INSULIN PREPARATIONS FOR PULMONARY DELIVERY | Novo Nordisk A/S (DK) | 2001-08-08 | — | — | EP | claimed |
| US-6268343-B1 | HUMAN GLUCAGON-LIKE PEPTIDE-1; MORE PROTRACTED PROFILE OF ACTION THAN THE PARENT PEPTIDES; TREATING DIABETES AND OBESITY; Liraglutide | NOVO NORDISK A/S (DK) | 2001-07-31 | — | — | US | claimed |
| US-6174856-B1 | AQUEOUS PARENTERAL INSULIN MIXTURE STABILIZED WITH A GLYCYLGLYCINE BUFFER AND CALCIUM OR MAGNESIUM IONS | NOVO NORDISK A/S (DK) | 2001-01-16 | — | — | US | claimed |
| EP-1044016-A1 | STABILISED INSULIN COMPOSITIONS | NOVO NORDISK A/S (DK) | 2000-10-18 | — | — | EP | claimed |
| WO-2000023098-A1 | STABLE CONCENTRATED INSULIN PREPARATIONS FOR PULMONARY DELIVERY | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | claimed |
| WO-2000023099-A1 | INSULIN PREPARATIONS FOR PULMONARY DELIVERY CONTAINING MENTHOL | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | claimed |
| WO-1999034821-A1 | STABILISED INSULIN COMPOSITIONS | NOVO NORDISK A/S (DK) | 1999-07-15 | — | — | WO | claimed |
| US-4097665-A | Diacylnucleosides and process for preparing the same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-06-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11965039-B2 | Compstatin analogues and their medical uses | C1QBP, C9, VIP | TSHR 1041/4885LMNA 1380/4885NFKB1 2017/4885 |
| US-20230405087-A9 | ACYLATED GLP-1/GLP-2 DUAL AGONISTS | GLP1R, GIPR, GPR119 | TSHR 313/4885LMNA 2721/4885NFKB1 4088/4885 |
| US-20230340039-A1 | NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | TSHR 259/4885LMNA 2884/4885NFKB1 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.